10x Genomics $TXG Shares Purchased by Amundi

Amundi boosted its stake in 10x Genomics (NASDAQ:TXG) by 16,013.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 320,340 shares of the company’s stock after purchasing an additional 318,352 shares during the period. Amundi owned approximately 0.26% of 10x Genomics worth $2,553,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in TXG. Iron Triangle Partners LP acquired a new stake in 10x Genomics in the 1st quarter valued at $8,730,000. Two Sigma Investments LP boosted its position in 10x Genomics by 291.2% in the 4th quarter. Two Sigma Investments LP now owns 1,319,487 shares of the company’s stock valued at $18,948,000 after buying an additional 982,203 shares during the last quarter. ARK Investment Management LLC boosted its position in 10x Genomics by 7.5% in the 1st quarter. ARK Investment Management LLC now owns 12,845,713 shares of the company’s stock valued at $112,143,000 after buying an additional 901,656 shares during the last quarter. Two Sigma Advisers LP boosted its position in 10x Genomics by 240.6% in the 4th quarter. Two Sigma Advisers LP now owns 1,236,200 shares of the company’s stock valued at $17,752,000 after buying an additional 873,200 shares during the last quarter. Finally, Trexquant Investment LP boosted its position in 10x Genomics by 91.8% in the 1st quarter. Trexquant Investment LP now owns 1,140,288 shares of the company’s stock valued at $9,955,000 after buying an additional 545,677 shares during the last quarter. 84.68% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at 10x Genomics

In other 10x Genomics news, CEO Serge Saxonov sold 9,348 shares of the firm’s stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $13.79, for a total value of $128,908.92. Following the sale, the chief executive officer owned 945,892 shares in the company, valued at approximately $13,043,850.68. This trade represents a 0.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Benjamin J. Hindson sold 7,486 shares of the firm’s stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $13.79, for a total transaction of $103,231.94. Following the completion of the sale, the insider owned 440,888 shares in the company, valued at $6,079,845.52. The trade was a 1.67% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 39,149 shares of company stock worth $539,865. 9.39% of the stock is owned by company insiders.

10x Genomics Trading Up 3.7%

Shares of NASDAQ:TXG opened at $13.06 on Friday. The firm’s 50 day moving average is $13.22 and its two-hundred day moving average is $10.80. 10x Genomics has a 52 week low of $6.78 and a 52 week high of $24.38. The firm has a market capitalization of $1.63 billion, a P/E ratio of -18.66 and a beta of 2.00.

10x Genomics (NASDAQ:TXG) last announced its quarterly earnings results on Thursday, August 7th. The company reported $0.28 EPS for the quarter, beating the consensus estimate of ($0.35) by $0.63. 10x Genomics had a negative net margin of 13.13% and a negative return on equity of 12.88%. The company had revenue of $172.91 million for the quarter, compared to analyst estimates of $139.36 million. During the same quarter last year, the business earned ($0.32) earnings per share. 10x Genomics’s revenue was up 12.9% compared to the same quarter last year. 10x Genomics has set its Q3 2025 guidance at EPS. Analysts predict that 10x Genomics will post -1.43 EPS for the current year.

Wall Street Analyst Weigh In

TXG has been the subject of a number of analyst reports. Deutsche Bank Aktiengesellschaft set a $14.00 price objective on shares of 10x Genomics and gave the company a “hold” rating in a research report on Friday, August 8th. Stephens reissued an “overweight” rating and issued a $14.00 price objective on shares of 10x Genomics in a research report on Thursday, May 15th. UBS Group upped their price objective on shares of 10x Genomics from $12.00 to $13.00 and gave the company a “neutral” rating in a research report on Friday, August 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of 10x Genomics in a research report on Saturday, August 30th. Finally, Barclays reaffirmed an “overweight” rating and set a $15.00 price target (up previously from $13.00) on shares of 10x Genomics in a research report on Friday, August 8th. Six investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $13.65.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.